Automated Cell Counters Market Size & Share, Growth Analysis Forecast 2022-2028

Industry Insights

[219+ Pages Report] According to Facts and Factors, the global automated cell counters market size was worth USD 6,193.10 million in 2021 and is estimated to grow to USD 8,539.31 million by 2028, with a compound annual growth rate (CAGR) of approximately 5.50% over the forecast period. The report analyzes the automated cell counters market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the automated cell counters market.

Market Overview

An automatic cell counter is an electronic device that can automatically count cells of animals, humans, plants, viruses, and bacteria, in addition to cells of other origins. The cell counting process begins with a partial loading into the automated cytometer, which is then passed through a narrow tube. The growth of the market is mainly driven by factors such as increasing funding for cell research, increasing prevalence of chronic and infectious diseases, and growth of biotechnology and pharmaceutical industries. Biological products, developing innovative solutions, improving image analysis, and the growing use of broadband. Flow cytometer and automated hematology analyzer.

On the other hand, the high cost of cell analysis is said to hinder the growth of the market to some extent. At the same time, growing incidences of blood-related issues, increased collaborations between market players, and supportive government initiatives are expected to offer lucrative opportunities for market players.

COVID-19 Impact:

The COVID-19 pandemic has impacted the businesses of automated cell counters. The COVID-19 pandemic spread throughout the world as strict lock-downs are implemented by governments and shut down companies. Thus, the movement of people is restricted during the covid-19 pandemic. The global automated cell counters market is likely to be impacted considerably during the forecast period.

Key Insights

• The global automated cell counters market accounted for USD 6193.10 million in 2021.
• By Type, the systems type segment dominated with accounted significant market share in 2021.
• In 2021, North America captured the largest revenue share of the global market.
• The global automated cell counters market is projected to grow at a CAGR of 5.50% from 2022 to 2028.
• By Application, the blood analysis segment accounted significant amount of market share in 2021.
• The growth factors for the market are increasing funding for cell research, increasing prevalence of chronic and infectious diseases, and growth of biotechnology and pharmaceutical industries all over the world which drive the market growth during the forecast period.

Growth Drivers

• The increasing rate of patients aids the global market growth

The global automated cell counting market is mainly driven by the increasing rate of target diseases like HIV, measles, diphtheria, and chronic diseases like cancer, hemophilia, and some other blood disorders. The World Health Organization says nearly 37.7 million people worldwide will be infected with HIV by the end of 2020. Additionally, 680,000 people will die from HIV-related causes in 2020, while 1.5 million people will likely be infected with HIV in the coming years. According to the National Haemophilia Foundation, nearly 33,000 people have hemophilia in the United States, 60% of which are severe.

Accordingly, the increase in infectious disease cases is likely to spur the significant growth of the automated cell counting industry. In addition, higher rates of use of devices such as b-cell markers to perform b-cell counts for counting interstitial cells, cell counting microscopes, and image analysis software like stereoscopic cell counting in ImageJand cell counting in Fiji which enables accurate cell counting and viability (through plating and CFU counting) of blood cells are also driving the market growth significantly.

Restraints

• The high-risk involvement may hamper the global market growth

The key restraints for the automated cell counters market are the high cost of complex cell counting technologies, lack of experienced professionals, and product recalls of hematology analyzers. Major restraint that is expected to impede the growth of the global automated cell counters market during the forecast period.

Opportunities

• The supportive government initiatives and rising chronic diseases bring up several growth opportunities

Government measures promoting the development of cell therapies, where cell counting plays an important role, are driving the market growth prospects in the future. Europe is a world leader in cell research and gene therapy (CGT) as it is home to 16 of the world's top 50 universities for life sciences. According to a survey by McKinsey, the European Union will invest around 7 billion euros in health research between 2021 and 2027 as part of the Horizon Europe initiative. Additionally, in the fiscal year 2020, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) provided nearly 50 million people with HIV testing and funded antiretroviral therapy to save approximately 18.2 lives. Million men, women, and children.

In addition, the increasing prevalence of blood-related chronic diseases will likely contribute to the expansion of this market. According to a study in 2020, the worldwide prevalence of leukemia is 27,519 people, with 311,59 deaths from the disease. Due to these disorders' prevalence and mortality rate, the adoption rate will increase, thus leading to disproportionate market growth in the future.

Challenges

• The high cost of automated cells counters a global challenge: the high cost of installing and maintaining them is a global challenge as it hinders the adoption of these types of equipment by hospitals and other end users.
• The lack of skilled professionals is also a barrier to market growth due to the increase of patients with various chronic diseases such as cancer, diabetes, strokes, and others, requiring more skilled professionals for better and faster treatment.

Segmentation Analysis

The global automated cell counters market is segregated on the basis of product, application, and region.

By product, the market is divided into system types. Among these, the system types segment dominates the market, accounting for a significant percentage of global sales due to the increasing demand for automated cell counters systems. Also, it will grow with the highest CAGR during the forecast period.

By Application, the market is bifurcated into blood analysis, urine analysis, microbial cell count, cell line viability, and others. Over the forecast period, the blood analysis segment is expected to develop at the fastest rate due to the increased blood checkups for every Type of treatment that support the growth of the blood analysis segment.

Report Scope

Recent Developments

• March 2022-Erasmus University Medical Center (Erasmus MC) in the Netherlands has signed a digital pathology contract with Sectra, an international medical imaging company. And network security companies. As a result, pathologists will be able to examine and collaborate with cases in a way that microscopy cannot. It will improve cancer care in the future by reducing variance and increasing the efficiency of baseline diagnoses.
• June 2021-CytoSMART Technologies has created one of the first fluorescent cell counters. CytoSMART Exact FL is a highly autonomous dual fluorescence cell counter with artificial intelligence (A.I.) algorithms that provide extremely reliable image recognition.

Regional Landscape

• The presence of market players and advancements help North America dominate the global market

North America is leading the automated cell counting device market due to the proliferation of chronic diseases such as heart and blood disorders. In addition, the improvement of healthcare infrastructure and the expansion of government-funded stem cell research and development activities will accelerate the growth of the automated cell counting devices market in the region. this. The National Cancer Institute estimates that there are 16.9 million cancer survivors in the United States in 2020, and by 2030, the number of cancer survivors is expected to reach 22.2 million. Apart from that, given the popularity of a wide range of clinical research and biopharmaceutical companies in the Asia-Pacific region, the automated cell counter market is expected to grow significantly in the Asia-Pacific region.

Some of the leading players in the global market include 

• Biotek Instruments Inc. 
• Bio-Rad Laboratories Inc. 
• Danaher Corporation 
• Alere Inc. 
• F. Hoffmann-La Roche Ltd 
• ChemoMetec A/S 
• Beckman Coulter Inc. 
• Logos Biosystems 
• NanoEnTek Inc. 
• Olympus Corporation.

The global automated cell counters market is segmented as follows:

By Product

• Systems Type
• Reagents & Consumables

By Application

• Blood Analysis
• Urine Analysis
• Microbial Cell Count
• Cell Line Viability
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America